Fidelity International’s Cytek Biosciences CTKB Stock Holding History

Fidelity International’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-573,600	Closed	-$3.18M	–	928
2024 Q3	$3.18M	Hold	573,600	–	–	﹤0.01%	665
2024 Q2	$3.2M	Hold	573,600	–	–	﹤0.01%	652
2024 Q1	$3.85M	Hold	573,600	–	–	﹤0.01%	622
2023 Q4	$5.23M	Hold	573,600	–	–	0.01%	568
2023 Q3	$3.17M	Hold	573,600	–	–	﹤0.01%	597
2023 Q2	$4.9M	Sell	573,600 -1,953	-0.3%	-$17.5K	0.01%	561
2023 Q1	$5.29M	Sell	575,553 -7,809	-1%	-$84K	0.01%	554
2022 Q4	$5.96M	Hold	583,362	–	–	0.01%	553
2022 Q3	$8.59M	Hold	583,362	–	–	0.01%	513
2022 Q2	$6.26M	Hold	583,362	–	–	0.01%	557
2022 Q1	$6.29M	Sell	583,362 -2,083,238	-78%	-$28.1M	0.01%	581
2021 Q4	$43.5M	Hold	2,666,600	–	–	0.04%	327
2021 Q3	$57.1M	Buy	+2,666,600	New	+$62.7M	0.06%	280

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity International's CTKB Position: Q4 2024 in Review

Fidelity International sold out of Cytek Biosciences (CTKB) in Q4 2024, closing a stake of 573,600 shares — an estimated $3.18M sold.

Fidelity International first reported a position in CTKB in Q3 2021 and held it in 13 quarters. The position peaked at $57.1M in Q3 2021. 152 funds tracked by Wall St. Rank hold CTKB as of Q4 2024.

Fidelity International reported no remaining Cytek Biosciences position as of Q4 2024 after selling out during the quarter.
Fidelity International sold 573,600 Cytek Biosciences shares in Q4 2024, an estimated $3.18M.
Fidelity International first reported a position in Cytek Biosciences in Q3 2021 and held it in 13 quarters.
Fidelity International's Cytek Biosciences position peaked at $57.1M in Q3 2021.
152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2024.

Based on Fidelity International's 13F filing for Q4 2024, filed 13 Feb 2025.